| Report Date | |
| Manager | |
| Fund Name | |
| Strategy | |
| Latest Return Date | |
| Latest Return | |
| Latest 6 Months | |
| Latest 12 Months | |
| Latest 24 Months (pa) | |
| Annualised Since Inception | |
| Inception Date | |
| FUM (millions) | |
| Fund Overview | The overriding objective of the Concentrated Australian Equities Fund is to seek investment opportunities which are under-appreciated and have the potential to deliver positive earnings, while satisfying our stringent quality criteria. Bennelong's investment process combines bottom-up fundamental analysis together with proprietary investment tools which are used to build and maintain high quality portfolios that are risk aware. The portfolio typically consists of 20-35 high-conviction stocks from the S&P/ASX 300 Index. The Fund may invest in securities listed on other exchanges where such securities relate to ASX-listed securities. Derivative instruments are mainly used to replicate underlying positions and hedge market and company specific risks. |
| Manager Comments | The Fund returned +5.51% over the December quarter versus the Index's +0.68%. The main contributor to the quarterly return was the Fund's outsized position in the healthcare sector, and in particular its positions in Fisher & Paykel Healthcare and CSL. The other main contributor to the Fund's relative outperformance was avoiding the banks' underperformance - the Fund owns no banks. There were detractors, however they didn't detract significantly from performance. The largest detractor was Afterpay, which gave back some of the outperformance delivered in previous periods. Bennelong believe the many social, political and economic uncertainties that overshadowed markets in 2019 remain. They expect the ASX to produce reasonable returns over the medium term, albeit with ups and downs along the way. The Fund is selectively invested in a group of high quality growth stocks including names such as CSL and Fisher & Paykel Healthcare. |
| More Information |
